These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 31710479)

  • 21. Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease.
    Ren J; Ojeda I; Patel M; Johnson ME; Lee H
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2349-2353. PubMed ID: 31201062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV.
    Nair AG; Zeng Q; Selyutin O; Rosenblum SB; Jiang Y; Yang DY; Keertikar K; Zhou G; Dwyer M; Kim SH; Shankar B; Yu W; Tong L; Chen L; Mazzola R; Caldwell J; Tang H; Agrawal S; Liu R; Kong R; Ingravallo P; Xia E; Zhai Y; Nomeir A; Asante-Appiah E; Kozlowski JA
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1954-1957. PubMed ID: 29653894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and biological evaluation of new potent and selective HCV NS5A inhibitors.
    Shi J; Zhou L; Amblard F; Bobeck DR; Zhang H; Liu P; Bondada L; McBrayer TR; Tharnish PM; Whitaker T; Coats SJ; Schinazi RF
    Bioorg Med Chem Lett; 2012 May; 22(10):3488-91. PubMed ID: 22507961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi
    Taylor JG; Zipfel S; Ramey K; Vivian R; Schrier A; Karki KK; Katana A; Kato D; Kobayashi T; Martinez R; Sangi M; Siegel D; Tran CV; Yang ZY; Zablocki J; Yang CY; Wang Y; Wang K; Chan K; Barauskas O; Cheng G; Jin D; Schultz BE; Appleby T; Villaseñor AG; Link JO
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2428-2436. PubMed ID: 31133531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of potent macrocyclic HCV NS5A inhibitors.
    Yu W; Vibulbhan B; Rosenblum SB; Martin GS; Vellekoop AS; Holst CL; Coburn CA; Wong M; Selyutin O; Ji T; Zhong B; Hu B; Chen L; Dwyer MP; Jiang Y; Nair AG; Tong L; Zeng Q; Agrawal S; Carr D; Rokosz L; Liu R; Curry S; McMonagle P; Ingravallo P; Lahser F; Asante-Appiah E; Fells J; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3793-9. PubMed ID: 27282743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.
    Lindström I; Kjellin M; Palanisamy N; Bondeson K; Wesslén L; Lannergard A; Lennerstrand J
    Infect Dis (Lond); 2015 Aug; 47(8):555-62. PubMed ID: 25851241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies.
    Lopez OD; Nguyen VN; St Laurent DR; Belema M; Serrano-Wu MH; Goodrich JT; Yang F; Qiu Y; Ripka AS; Nower PT; Valera L; Liu M; O'Boyle DR; Sun JH; Fridell RA; Lemm JA; Gao M; Good AC; Meanwell NA; Snyder LB
    Bioorg Med Chem Lett; 2013 Feb; 23(3):779-84. PubMed ID: 23273521
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Ng TI; Krishnan P; Pilot-Matias T; Kati W; Schnell G; Beyer J; Reisch T; Lu L; Dekhtyar T; Irvin M; Tripathi R; Maring C; Randolph JT; Wagner R; Collins C
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
    Zhou S; Mahmoud S; Liu P; Zhou L; Ehteshami M; Bassit L; Tao S; Domaoal RA; Sari O; Schutter C; Amiralaei S; Khalil A; Ollinger Russell O; McBrayer T; Whitaker T; Abou-Taleb N; Amblard F; Coats SJ; Schinazi RF
    J Med Chem; 2017 Jul; 60(13):5424-5437. PubMed ID: 28595015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pan-genotypic Hepatitis C Virus NS5A amplification method for reliable genotyping and resistance testing.
    Walker A; Ennker KS; Kaiser R; Lübke N; Timm J
    J Clin Virol; 2019 Apr; 113():8-13. PubMed ID: 30771598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Comprehensive Insight into the Chemical Space and ADME Features of Small Molecule NS5A Inhibitors.
    Ivanenkov YA; Veselov MS; Shakhbazyan AG; Aladinskiy VA; Aladinskaya AV; Yartseva SM; Majouga AG; Vantskul AS; Leonov SV; Ivachtchenko AV; Koteliansky VE
    Curr Top Med Chem; 2016; 16(12):1372-82. PubMed ID: 26585933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Orally bioavailable HCV NS5A inhibitors of unsymmetrical structural class.
    Nakamura H; Fujioka S; Terui T; Okuda S; Kondo K; Tamatani Y; Akagi Y; Komoda Y; Kinoshita W; Ito S; Maeda K; Ukaji Y; Inaba T
    Bioorg Med Chem Lett; 2020 Sep; 30(17):127361. PubMed ID: 32738974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones.
    Murayama A; Fujiwara K; Yamada N; Shiina M; Aly HH; Masaki T; Muramatsu M; Wakita T; Kato T
    Antiviral Res; 2018 Oct; 158():161-170. PubMed ID: 30118732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.
    Sun JH; O'Boyle DR; Fridell RA; Langley DR; Wang C; Roberts SB; Nower P; Johnson BM; Moulin F; Nophsker MJ; Wang YK; Liu M; Rigat K; Tu Y; Hewawasam P; Kadow J; Meanwell NA; Cockett M; Lemm JA; Kramer M; Belema M; Gao M
    Nature; 2015 Nov; 527(7577):245-8. PubMed ID: 26536115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor.
    Plaza Z; Soriano V; Vispo E; del Mar Gonzalez M; Barreiro P; Seclén E; Poveda E
    Antivir Ther; 2012; 17(5):921-6. PubMed ID: 22436385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of 2-(4-sulfonamidophenyl)-indole 3-carboxamides as potent and selective inhibitors with broad hepatitis C virus genotype activity targeting HCV NS4B.
    Zhang N; Turpoff A; Zhang X; Huang S; Liu Y; Almstead N; Njoroge FG; Gu Z; Graci J; Jung SP; Pichardo J; Colacino J; Lahser F; Ingravallo P; Weetall M; Nomeir A; Karp GM
    Bioorg Med Chem Lett; 2016 Jan; 26(2):594-601. PubMed ID: 26652483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of imidazo[2,1-b]thiazole HCV NS4B inhibitors exhibiting synergistic effect with other direct-acting antiviral agents.
    Wang NY; Xu Y; Zuo WQ; Xiao KJ; Liu L; Zeng XX; You XY; Zhang LD; Gao C; Liu ZH; Ye TH; Xia Y; Xiong Y; Song XJ; Lei Q; Peng CT; Tang H; Yang SY; Wei YQ; Yu LT
    J Med Chem; 2015 Mar; 58(6):2764-78. PubMed ID: 25710739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions.
    Yu W; Tong L; Selyutin O; Chen L; Hu B; Zhong B; Hao J; Ji T; Zan S; Yin J; Ruck RT; Curry S; McMonagle P; Agrawal S; Rokosz L; Carr D; Ingravallo P; Bystol K; Lahser F; Liu R; Chen S; Feng KI; Cartwright M; Asante-Appiah E; Kozlowski JA
    J Med Chem; 2018 May; 61(9):3984-4003. PubMed ID: 29681153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
    Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
    Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expanding the chemical space of anti-HCV NS5A inhibitors by stereochemical exchange and peptidomimetic approaches.
    Ramsis TM; Abdel Karim SE; Vassilaki N; Frakolaki E; Kamal AAM; Zoidis G; Ahmed NS; Abadi AH
    Arch Pharm (Weinheim); 2018 Jul; 351(7):e1800017. PubMed ID: 29799645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.